Physicians' Academy for Cardiovascular Education

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

Video navigation menu

  • Expected effects of incretin-based therapies for T2DM 0:32
  • Looking at the exendin-4-based GLP-1RA trial data in detail 2:48
  • Scrutinizing the study characteristics of the human analogue GLP-1RA trial data 5:19
  • What can explain the differences seen between trials testing various GLP-1RAs? 16:49
  • Impact of GLP-1RA on guidelines 18:30

Educational information

This lecture was part of a CME accredited symposium: 'Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice?', held during ESC 2018 in Munich, Germany.


Professor Lars Rydén, MD - Senior Professor of Cardiology, Karolinska Institute, Stockholm, Sweden


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk

View slides of prof. Lars Rydén


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: